Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep

被引:0
作者
Wong, H
Rurak, DW
Kumar, S
Kwan, E
Abbott, FS
Riggs, KW
机构
[1] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada
[2] Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Obstet & Gynecol, Fac Med, Vancouver, BC V6T 1Z3, Canada
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dose-dependent pharmacokinetics and metabolism of valproic acid (VPA) were studied in newborn and adult sheep to assess age-related differences in plasma protein binding and metabolic elimination. Newborn lambs received either a 10- (n = 8), 50- (n = 5), 100- (n = 4), or 250-mg/kg (n = 4) VPA i.v. bolus. Individual adult sheep (n = 5) received all four doses in a random order with an appropriate washout period between experiments. Unbound or metabolic clearance of VPA was significantly higher in adult sheep at the two lower doses when compared with lambs, and similar to the lambs at the two higher doses. Plasma protein binding was nonlinear at all doses. Estimates of binding capacity (B-max1)at the saturable site were higher in adults (91.8 mug/ml) when compared with lambs (44.9 mug/ml), whereas the opposite trend was observed for binding affinity [K-d1 = 9.6 mug/ml (adult) versus 3.2 mug/ml (lambs)]. Characterization of developmental differences in overall VPA metabolic elimination involved fitting of unbound VPA plasma concentration data to a two-compartment model with Michaelis-Menten elimination. This resulted in similar in vivo estimates of apparent V-max [445.0 mug/min/kg (adult) versus 429.9 mug/min/kg (lambs)]. However, apparent K-m estimates appeared to be higher in lambs [30.0 mug/ml (adult) versus 69.6 mug/ml (lambs)]. Similar findings were obtained from in vivo estimates of V-max and K-m for VPA glucuronidation obtained from VPA-glucuronide metabolite urinary excretion data. Thus, it appears that age-related differences in metabolic clearance may be related to differences in the apparent in vivo K-m as opposed to V-max of VPA glucuronidation.
引用
收藏
页码:664 / 675
页数:12
相关论文
共 46 条
[1]   EFFECT OF VALPROATE DOSE ON FORMATION OF HEPATOTOXIC METABOLITES [J].
ANDERSON, GD ;
ACHEAMPONG, AA ;
WILENSKY, AJ ;
LEVY, RH .
EPILEPSIA, 1992, 33 (04) :736-742
[2]  
[Anonymous], 2010, CLIN PHARMACOKINET
[3]  
[Anonymous], 1959, Metabolism in the Rumen
[4]   PLASMA-PROTEIN BINDING-KINETICS OF VALPROIC ACID OVER A BROAD DOSAGE RANGE - THERAPEUTIC IMPLICATIONS [J].
BELLVER, MJG ;
SANCHEZ, MJG ;
GONZALEZ, ACA ;
BUELGA, DS ;
DOMINGUEZGIL, A .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1993, 18 (03) :191-197
[5]  
Bourne DWA, 1995, MATH MODELING PHARMA
[6]   VALPROIC ACID DOSAGE AND PLASMA-PROTEIN BINDING AND CLEARANCE [J].
BOWDLE, TA ;
PATEL, IH ;
LEVY, RH ;
WILENSKY, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (04) :486-492
[7]  
D'Argenio DZ, 1997, ADAPT 2 USERS GUIDE
[8]   VALPROIC ACID - A REAPPRAISAL OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL EFFICACY IN EPILEPSY [J].
DAVIS, R ;
PETERS, DH ;
MCTAVISH, D .
DRUGS, 1994, 47 (02) :332-372
[9]  
DICKINSON RG, 1979, J PHARMACOL EXP THER, V211, P583
[10]   URINARY-EXCRETION OF VALPROATE AND SOME METABOLITES IN CHRONICALLY TREATED PATIENTS [J].
DICKINSON, RG ;
HOOPER, WD ;
DUNSTAN, PR ;
EADIE, MJ .
THERAPEUTIC DRUG MONITORING, 1989, 11 (02) :127-133